RISEDRONATE SODIUM
Clinical safety rating: avoid
Contraindicated (not allowed)
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, preventing osteoclast attachment and inducing osteoclast apoptosis.
| Metabolism | Not metabolized; eliminated unchanged primarily by renal excretion via glomerular filtration and tubular secretion. |
| Excretion | Renal excretion (unchanged, via glomerular filtration and active tubular secretion): 50-65% of absorbed dose. Fecal excretion: minor, <5% as unabsorbed drug. Biliary excretion: negligible. |
| Half-life | Terminal elimination half-life: 480 hours (20 days) due to slow release from bone; clinical context: supports once-weekly dosing for osteoporosis. |
| Protein binding | ~24% bound to plasma proteins, primarily albumin. Binding is concentration-independent and low affinity. |
| Volume of Distribution | Steady-state Vd: 6.3 L/kg; extensive distribution into bone mineral (hydroxyapatite) and low soft tissue penetration. |
| Bioavailability | Oral: 0.63% (fasted state, mean; range 0.5–0.8%). Food, calcium, and iron significantly reduce absorption; must be taken with plain water on empty stomach. |
| Onset of Action | Oral: Reduction of bone resorption markers observed within 14 days; maximal effect on bone turnover in 3-6 months. IV: Not clinically applicable. |
| Duration of Action | Bone turnover suppression persists for up to 12 months after discontinuation due to bone binding; clinical note: residual effects require consideration when sequencing antiresorptive therapy. |
| Molecular Weight | 350.13 Da (risedronate sodium; risedronic acid: 283.1 Da) |
35 mg orally once weekly or 5 mg orally once daily, taken at least 30 minutes before the first food or beverage of the day with 6-8 ounces of plain water. For Paget disease: 30 mg orally once daily for 2 months.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | Contraindicated if creatinine clearance <30 mL/min. For CrCl 30-59 mL/min: no dose adjustment needed. For CrCl <30 mL/min: not recommended. |
| Liver impairment | No specific guidelines; hepatic impairment does not significantly alter risedronate pharmacokinetics. Use with caution in severe hepatic impairment due to potential comorbidities. |
| Pediatric use | Safety and efficacy not established in children <18 years; not recommended. |
| Geriatric use | No specific dose adjustment required for age alone; ensure adequate calcium and vitamin D intake, monitor renal function as age-related decline may occur. |
| 1st trimester | Contraindicated. Teratogenic effects observed in animal studies; theoretical risk of fetal skeletal abnormalities. |
| 2nd trimester | Contraindicated. Risk of fetal hypocalcemia and skeletal toxicity. |
| 3rd trimester | Contraindicated. Potential for neonatal hypocalcemia and long bone deformities. |
Clinical note
Calcium supplements and other oral medications can interfere with absorption Risk of esophageal irritation and osteonecrosis of the jaw.
| Placental transfer | Yes. Bisphosphonates cross the placenta; fetal concentrations may be comparable to maternal levels. |
| Breastfeeding | Excreted in animal milk; human data absent. Theoretical risk of infant hypocalcemia and bone development effects. Avoid use during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Common Effects | Paget's disease |
| Serious Effects |
HypocalcemiaSevere renal impairment (CrCl <30 mL/min)PregnancyKnown hypersensitivity to risedronate or bisphosphonatesInability to stand or sit upright for at least 30 minutes
| Precautions | Risk of atypical femur fractures, Osteonecrosis of the jaw, especially with invasive dental procedures, Severe musculoskeletal pain, Renal impairment: not recommended in patients with CrCl < 30 mL/min, Electrolyte disturbances: hypocalcemia must be corrected before initiation |
| Food/Dietary | Avoid food, beverages (other than plain water), and other oral medications for at least 30 minutes after taking risedronate. Food, especially calcium-rich products (e.g., milk, dairy, fortified juices), antacids, and mineral supplements significantly reduce absorption. Wait at least 30 minutes after dosing before consuming any food or drink other than plain water. Do not take with mineral water, coffee, tea, or juice. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | Risedronate sodium is pregnancy category C. In animal studies, maternal toxicity at high doses resulted in fetal skeletal abnormalities and reduced fetal weight. There are no adequate and well-controlled studies in pregnant women. First trimester: theoretical risk of bisphosphonate incorporation into fetal bone matrix; second and third trimesters: potential for fetal bone abnormalities and neonatal hypocalcemia. Use only if clearly needed. |
| Fetal Monitoring | Monitor serum calcium, phosphate, and magnesium levels. Assess bone mineral density. Monitor fetal growth and development via ultrasound if used during pregnancy. Watch for maternal hypocalcemia. |
| Fertility Effects | No significant adverse effects on fertility reported in animal studies. Human data limited; theoretical risk due to bone metabolism alterations but generally considered minimal. |
| Clinical Pearls | Administer on an empty stomach at least 30 minutes before the first food, beverage, or other medication of the day with plain water (not mineral water). Avoid lying down for at least 30 minutes after taking to reduce esophageal irritation. Monitor serum calcium, phosphate, and vitamin D levels; hypocalcemia must be corrected before initiation. Use with caution in severe renal impairment (CrCl <30 mL/min); adjust dose or avoid. Long-term use (>3-5 years) warrants reassessment of fracture risk; consider drug holiday. Concomitant NSAIDs or aspirin may increase upper GI adverse events. Not recommended in pregnancy or breastfeeding. |
| Patient Advice | Take the tablet first thing in the morning with a full glass of plain water (6-8 oz) at least 30 minutes before any food, drink, or other medications. · Do not chew, crush, or suck the tablet; swallow it whole. · Remain upright (sitting or standing) for at least 30 minutes after taking the medication to prevent irritation of the esophagus. · Avoid lying down until after you have eaten your first meal of the day. · Take calcium and vitamin D supplements as recommended by your doctor, but do not take them at the same time as risedronate (separate by at least 30 minutes). · Report any symptoms of esophageal irritation such as difficulty or pain swallowing, chest pain, or severe heartburn. · Do not take the medication if you are unable to stand or sit upright for 30 minutes. · Inform your doctor if you have kidney disease, low blood calcium, or problems with your esophagus. |